Company profile
Karyopharm Therapeutics Inc.
NASDAQ: KPTI · Healthcare · Biotechnology
#314 of 1,418 Healthcare companies by revenue43rd-percentile growth
EA Score
49DFH 35DQ 68GM 46SS 63
v0.1 · 65/100 weight · provisional
↑ disclosure history, workforce scale · ↓ balance-sheet leverage, return on assets
Methodology →Revenue TTM
$151.1M
Rev growth YoY (TTM)
+6.3%
Net income (FY)
-$196.0M
Employees
228
as of 2026-08-13
Market cap
$46.0M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$146.1M$146.1M2025
Net income-$196.0M-$196.0M2025
Operating income-$90.7M-$90.7M2025
Total assets$108.4M$108.4M2025
Liabilities$401.3M$401.3M2025
Equity-$292.9M-$292.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License and Service98%
Health Care, Other2%
By geography
Not disclosed.
The read
What is Karyopharm Therapeutics Inc.’s revenue?
Karyopharm Therapeutics Inc. booked $146.1M in FY2025 revenue, growing 0.6% year over year — about the middle of the pack among Healthcare companies we track, at a -134.2% net margin.
Peers · Healthcare
Elite Pharmaceuticals, Inc.77B+GRAIL Inc.51DCronos Group Inc.69BiAnthus Capital Holdings, Inc.46DInfuSystem Holdings, Inc.80B+Beam Therapeutics Inc.62CNeighbors
Middlesex →Key facts
CEORichard A. Paulson
SectorHealthcare
IndustryBiotechnology
HeadquartersNewton, MA
ExchangeNASDAQ: KPTI
Employees228
IPO date2013-11-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.